other:
Western Blot:Article Title: Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes
Article Snippet: .. Western blotting was performed as described [ , ] using the following antibodies: rabbit polyclonal antibodies against MASTL (Abgent, San Diego, CA, USA); phospho-ENSA (Ser67)/ARPP19 (Ser62), ENSA, cleaved PARP (Asp214), AKT, phospho-Chk2 (Thr68) (Cell Signaling Technology, Danvers, MA, USA); rabbit monoclonal antibody against phospho-c-Myc (Ser 62) (Abcam, Cambridge, UK); mouse monoclonal antibody against caspase-2 (Cell Signaling Technology, Danvers, MA, USA), and c-Myc (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); and a mouse polyclonal antibody against β-actin (Santa Cruz Biotechnology, Inc.). .. The PP2A activity assay was performed as previously described [ ], and the PP2A phosphatase assay according to the manufacturer’s protocol (RediPlate 96 EnzChek serine/threonine phosphatase assay kit; Invitrogen).
Article Title: Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.
Article Snippet: .. Western blotting was performed as described [30,32] using the following antibodies: rabbit polyclonal antibodies against MASTL (Abgent, San Diego, CA, USA); phosphoENSA (Ser67)/ARPP19 (Ser62), ENSA, cleaved PARP (Asp214), AKT, phospho-Chk2 (Thr68) (Cell Signaling Technology, Danvers, MA, USA); rabbit monoclonal antibody against phospho-c-Myc (Ser 62) (Abcam, Cambridge, UK); mouse monoclonal antibody against caspase-2 (Cell Signaling Technology, Danvers, MA, USA), and c-Myc (Santa Cruz Biotechnology, Inc., Dallas, TX, USA); and a mouse polyclonal antibody against β-actin (Santa Cruz Biotechnology, Inc.). .. The PP2A activity assay was performed as previously described [30], and the PP2A phosphatase assay according to the manufacturer’s protocol (RediPlate 96 EnzChek serine/threonine phosphatase assay kit; Invitrogen).
SDS Page:Article Title: Pharmaceutical composition for preventing or treating cancer, containing N-1H-benzimidazol-2-yl-3-(1H-pyrrole-1-yl)benzamide as active ingredient
Article Snippet: .. 20 μg of protein was separated by SDS-PAGE electrophoresis and transferred to a PVDF membrane, and the following specific antibodies were used: rabbit polyclonal antibody MASTL (Abgent); phospho-ENSA (Ser67)/ARPP19 (Ser62) (#5240), ENSA (#11915S), cleaved PARP (Asp214) (#9541), AKT (#9272), phospho-AKT (ser473) (#9271), phospho-GSK-3α/β (Ser21/9) (#9331), phospho-p70S6K (The 288) (#9205) and phospho-Chk2 (Thr68) (#2661; Cell Signaling Technology, MA); p70S6K (sc-230; Santa Cruz Biotechnology, CA, USA), phospho-H3 (S10) (06-570, Merck, NJ); mouse monoclonal antibody caspase-2 (#2224S). .. In addition, mouse polyclonal antibody β-actin (C4; Santa Cruz Biotechnology, CA, USA) was used as a loading control, it was washed with 1×PBS/0.1% Tween 20, and the binding protein was detected using HRP-binding secondary antibody and improved chemiluminescence detection system.
Electrophoresis:Article Title: Pharmaceutical composition for preventing or treating cancer, containing N-1H-benzimidazol-2-yl-3-(1H-pyrrole-1-yl)benzamide as active ingredient
Article Snippet: .. 20 μg of protein was separated by SDS-PAGE electrophoresis and transferred to a PVDF membrane, and the following specific antibodies were used: rabbit polyclonal antibody MASTL (Abgent); phospho-ENSA (Ser67)/ARPP19 (Ser62) (#5240), ENSA (#11915S), cleaved PARP (Asp214) (#9541), AKT (#9272), phospho-AKT (ser473) (#9271), phospho-GSK-3α/β (Ser21/9) (#9331), phospho-p70S6K (The 288) (#9205) and phospho-Chk2 (Thr68) (#2661; Cell Signaling Technology, MA); p70S6K (sc-230; Santa Cruz Biotechnology, CA, USA), phospho-H3 (S10) (06-570, Merck, NJ); mouse monoclonal antibody caspase-2 (#2224S). .. In addition, mouse polyclonal antibody β-actin (C4; Santa Cruz Biotechnology, CA, USA) was used as a loading control, it was washed with 1×PBS/0.1% Tween 20, and the binding protein was detected using HRP-binding secondary antibody and improved chemiluminescence detection system.
Membrane:Article Title: Pharmaceutical composition for preventing or treating cancer, containing N-1H-benzimidazol-2-yl-3-(1H-pyrrole-1-yl)benzamide as active ingredient
Article Snippet: .. 20 μg of protein was separated by SDS-PAGE electrophoresis and transferred to a PVDF membrane, and the following specific antibodies were used: rabbit polyclonal antibody MASTL (Abgent); phospho-ENSA (Ser67)/ARPP19 (Ser62) (#5240), ENSA (#11915S), cleaved PARP (Asp214) (#9541), AKT (#9272), phospho-AKT (ser473) (#9271), phospho-GSK-3α/β (Ser21/9) (#9331), phospho-p70S6K (The 288) (#9205) and phospho-Chk2 (Thr68) (#2661; Cell Signaling Technology, MA); p70S6K (sc-230; Santa Cruz Biotechnology, CA, USA), phospho-H3 (S10) (06-570, Merck, NJ); mouse monoclonal antibody caspase-2 (#2224S). .. In addition, mouse polyclonal antibody β-actin (C4; Santa Cruz Biotechnology, CA, USA) was used as a loading control, it was washed with 1×PBS/0.1% Tween 20, and the binding protein was detected using HRP-binding secondary antibody and improved chemiluminescence detection system.
|